FDA Approves Nucala for Hypereosinophilic Syndrome

TUESDAY, Sept. 29, 2020 — The U.S. Food and Drug Administration announced the approval last week of the first treatment for hypereosinophilic syndrome (HES) in more than a decade.
The drug, Nucala (mepolizumab), is approved for patients 12 years…
Source: Topamax